Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review

Cancer Treatment Reviews

Volumn 34, Issue 6, 2008, Pages 539-557

  Madarnas, Yolanda ^a   Trudeau, Maureen ^b   Franek, Jacob A ^c   McCready, David ^d   Pritchard, Kathleen I ^b   Messersmith, Hans ^c  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adjuvant Thearpy; Antibodies; Breast Neoplasms; Combined Modality Therapy; Early Breast Cancer; erbB 2; Herceptin; Monoclonal; Receptor; Trastuzumab

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ANEMIA; ARTHRALGIA; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKEMIA; LEUKOPENIA; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE; SIDE EFFECT; STOMATITIS; SYMPOSIUM; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; UNITED STATES; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 51449102098     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.03.013     Document Type: Review

References (65)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Genentech Inc. Herceptin (trastuzumab): full prescribing information [monograph on the Internet]. San Francisco (CA): Genentech. ; 2005 [cited 2006 March 24].
3. O'Reilly S.M., Branes D.M., Camplejohn R.S., Bartktova J., Gregory W.M., and Richards M.A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63 (1991) 444-446
4. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
5. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., and Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9 3 (1989) 1165-1172
6. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., and Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 7 (1994) 1829-1838
7. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11 3 (1991) 117-127
8. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 10 (1992) 4285-4289
9. Extra J.M., Cognetti F., Chan S., Maraninchi D., Snyder R., and Mauriac L. First-line trastuzumab (Herceptin (R)) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001). Breast Cancer Res Treat 82 Suppl 1 (2003) A217 [abstract]
10. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 11 (2001) 783-792
11. Piccart-Gebhart MJ. HERA trial [slides on the Internet]. 2005 American Society of Clinical Oncologists Virtual Meeting: advances in monoclonal antibody therapy for breast cancer scientific symposium.
12. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 353 16 (2005) 1659-1671
13. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369 (2007) 29-36
14. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Pawlicki M., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC > T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC > TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 94 Suppl 1 (2005) A1
15. Slamon D, Eiermann W, Pienkowski T, Martin M, et al. BCIRG 006: 2nd Interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients [slides on the internet]. In: 2006 annual San Antonio breast cancer symposium. ; 2007 [cited 2007 July 30:11pp].
16. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [slides on the Internet]. In: 2006 annual San Antonio breast cancer symposium virtual meeting. ; 2006 [cited 2007 July 30:42 slides].
17. Perez E.A., Suman V., Davidson N., Kauffman P.A., Martino S., Dakhil S.R., et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial [abstract]. J Clin Oncol 23 16S (2005) A556
18. Perez EA, Suman V, Davidson N, Martino S, Kauffman PA. Further analysis of NCCTG-N9831 [slides on the Internet]. In: 2005 American Society of Clinical Oncologists virtual meeting: advances in monoclonal antibody therapy for breast cancer scientific symposium. ; 2005 [cited 2005 June 10:24 slides].
19. Halyard M.Y., Pisansky T.M., Solin L.J., Marks L.B., Pierce L.J., Dueck A., et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from the North Central Cancer Treatment Group phase III trial N9831 [abstract]. J Clin Oncol 24 18S (2006) A523
20. Halyard MY, Pisansky TM, Pierce LJ, Solin LJ, Marks LB, Dueck A, et al. Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase III trial N9831 [slides on the Internet]. In: 2006 ASCO annual meeting. 60f5624ba07fd506fe310ee37a01d/?vgnextoid = 76f8201eb61a7010VgnVCM100000ed730ad1RCRD& vmview = abst_detail_view& confID = 40& abstractID = 34146http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe 310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmvi ew=abst_detail_view&confID=40&abstractID=34146; 2006 [cited 2006 September 27:17 slides].
21. Tan-Chiu E., Yothers G., Romond E.H., Geyer C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, Human Epidermal Growth Factor Receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 31 (2005) 7811-7819
22. Geyer C.E., Bryant J.L., Romond E.H., Ewer M.S., Keefe D.L., Shannon R.P., et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) > paclitaxel (T) vs. AC > T with trastuzumab (H) [abstract]. J Clin Oncol 24 18S (2006) A581
23. Geyer CE, Bryant J, Yothers G, Romond E, Ewer M, Keefe D, et al. Four year update of cardiac dysfunction on NSABP B-31: a randomized trail of AC > paclitaxel vs. AC > paclitaxel with trastuzumab in HER2 positive, node positive operable breast cancer [slides on the Internet] [abstract 581]. In: 2006 ASCO annual meeting. ; 2006 [cited 2006 September 27:22 slides].
24. Romond E.H., Perez E.A., Bryant J., Suman V., Geyer C.E., Davidson N., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353 16 (2005) 1673-1684
25. 25. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, et al. Joint analysis of NSABP-B-31 and NCCTG-N9831 [slides on the Internet]. 2005 American Society of Clinical Oncologists virtual meeting: advances in monoclonal antibody therapy for breast cancer scientific symposium. ; 2005 [cited 2005 June 10:21pp].
26. Joensuu H, Alanko T, Bono P, Jyrkkio S, Kokko R, Korhonen T, et al. Trastuzumab shows no short-term cardiac toxicity when given concomitantly with single-agent vinorelbine or docetaxel as adjuvant treatment for early breast cancer [slides on the Internet] [abstract 74]. 2003 ASCO annual meeting. ; 2003 [cited 2005 June 10:12 slides].
27. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New Engl J Med 354 8 (2006) 809-820
28. Sledge G, O'Neil A, Thor A, Kahanic SP, Zander PJ, et al. Adjuvant trastuzumab: long-term results of E2198 [slides on the Internet]. In: 2006 annual San Antonio breast cancer symposium. http://www.posters2view.com/sabcs06/view.php?nu=2075; 2007 [cited 2007 July 30:p. 1].
29. Sledge G.W., O'Neil A., Thor A., Kahanic S.P., Zander P.J., and Davidson N. Adjuvant trastuzumab: long-term results of E2198 [abstract]. Breast Cancer Res Treat 100 Suppl. 1 (2006) A2075
30. Buzdar A.U., Ibrahim N.K., Francis D., Booser D., Thomas E.S., Theriault R.L., et al. Significantly higher pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal group factor receptor 2-positive disease. J Clin Oncol 23 16 (2005) 3676-3685
31. Buzdar A.U., Valero V., Ibrahim N.K., Theriault R.L., Green M., Hunt K., et al. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population [abstract]. Breast Cancer Res Treat 94 Suppl. 1 (2005) A5049
32. Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13 1 (2007) 228-233
33. Chang H.R., Slamon D., Prati R., Glaspy J., Pegram M., Kass F.C., et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity [abstract]. J Clin Oncol 24 18S (2006) A10515
34. Suter T.M., Procter M., van Veldhuisen D.J., Muscholl M., Bergh J., Carlomagno C., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25 25 (2007) 3859-3865
35. Telli M.L., Hunt S.A., Carlson R.W., and Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25 23 (2007) 3525-3533
36. Perez E.A., Suman V., Davidson N., Kauffman P.A., Martino S., Dakhil S.R., et al. Effect of doxorubicin plus cyclophosphamid on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22 18 (2004) 3700-3704
37. Buzdar AU. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab [herceptin (H)], paclitaxel (P), and anthracycline-containing chemotherapy: Initial results of a randomized trial in operable breast cancer with HER-2 positive disease. [slides on the Internet]. In: 2004 ASCO annual meeting. ; 2004 [cited 2005 June 10].
38. Ghahramani P., Barton C., and Leyland-Jones B. Pharmacokinetics of herceptin administered three-weekly compared to weekly: a simulation based on date from the clinical studies [abstract]. Breast 12 S40 (2003) AP89
39. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel. J Clin Oncol 21 21 (2003) 3965-3971
40. Roche P.C., Suman V.J., Jenkins R.B., Davidson N.E., Martino S., Kaufman P.A., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 11 (2002) 855-857
41. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 19 (2006) 3032-3038
42. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131 1 (2007) 18
43. Hanna W., and O'Malley F. Updated recommendations from the HER2/neu consensus meeting: Toronto, Ontario, 7 September 2001. Curr Oncol. 9 Suppl. 1 (2002) S18-S20
44. Park K., Han S., Gwak G.H., Kim H.J., Kim J., and Kim K.M. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 98 3 (2006) 337-342
45. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 30 (2005) 7483-7490
46. Di L.A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 5 (2002) 1107-1116
47. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P., et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 16 (2006) 2428-2436
48. Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8 4 (2002) 1061-1067
49. Smith K.L., Dang C., and Seidman A.D. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 5 5 (2006) 619-629
50. Guarneri V., Lenihan D.J., Valero V., Durand J.B., Broglio K., Hess K.R., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 25 (2006) 4107-4115
51. Suter T.M., Cook-Bruns N., and Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13 3 (2004) 173-183
52. Nahta R., Takahashi T., Ueno N.T., Hung M.C., and Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 11 (2004) 3981-3986
53. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
54. Lu Y., Zi X., Zhao Y., Mascarenhas D., and Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93 24 (2001) 1852-1857
55. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2005. Toronto (Canada): Canadian Cancer Society/National Cancer Institute of Canada; 2005.
56. Spielmann M. Phase III randomized study of adjuvant docetaxel and epirubicin versus adjuvant cyclophosphamide, epirubicin, and fluorouracil with or without trastuzumab (herceptin) in women with nonmetastatic adenocarcinoma of the breast with lymph node invasion [database on the Internet] [protocol FRE-FNCLCC-PACS-04/005]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US). ; 2005 [cited 2005 June 15].
57. Pivot X. Phase III randomized study of 6 months versus 12 months adjuvant trastuzumab (herceptin) in women with nonmetastatic, resectable breast cancer [database on the Internet] [protocol INCA-PHARE]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US). ; 2006 September 23 [cited 2006 September 27].
58. Phase II randomized study of neoadjuvant docetaxel, doxorubicin hydrochloride, and cyclophosphamide versus doxorubicin and cyclophosphamide followed by paclitaxel and carboplatin with or without trastuzumab (herceptin) in patients with stage II or III breast cancer [database on the Internet] [protocol CHNMC-05015]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US). ; 2006 February 17 [cited 2006 September 27].
59. Graham M. Phase III randomized study of doxorubicin and cyclophosphamide with or without dexrazoxane, followed by paclitaxel with or without trastuzumab (herceptin), followed by surgery and radiotherapy with or without trastuzumab in women with HER-2+ stage IIIA or IIIB or regional stage IV breast cancer [database on the Internet] [protocol CLB-49808]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US). ; 2003 [cited 2005 June 15].
60. Chang H. Phase III randomized study of neoadjuvant docetaxel and carboplatin with versus without trastuzumab (herceptin®) in women with locally advanced breast cancer [database on the Internet] [protocol UCLA-9911084]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US). http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx; 2004 [cited 2005 June 15].
61. Jirau-Lucca G.A phase IIb, randomized, multicenter, noncomparitive pilot study of the safety and efficacy of three docetaxel-based chemotherapy regimens plus bevacizumab +/- trastuzumab for the adjuvant treatment of patients with node-positive and high-risk node-negative breast cancer [database on the Internet] [protocol DOCET_L_00714]. Bethesda (MD): National Cancer Institute Clinical Trials Database (US); 2007 [cited 2007 July 27].
62. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients With HER2/ErbB2 positive primary breast cancer [database on Internet] [protocol NCT00490139]. GSK Clinical Trials (MD): National Cancer Institute Clinical Trials Database (US). ; 2007 [cited 2007 July 27].
63. Conte. Chemotherapy plus lapatinib or trastuzumab or both in Her2+ primary breast cancer. A randomized phase IIb study with biomarker evaluation. [Database on the Internet] [protocol NCT00429299]. GSK Clinical Trials (MD): National Cancer Institute Clinical Trials Database (US); 2007 [cited 2007 July 27].
64. A randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. Breast International Group: Planned Clinical Trials. PrFont34Bin0BinSub0Frac0Def1Margin0Margin0Jc1Indent1440Lim0Li m1http://www.breastinternationalgroup.org/BIG/Clinical_Trials/Planned_tr ials/BIG_1-06_EGF106903_(Neo- ALLTO).aspx [database on Internet] [protocol EGF106903]; 2007 [cited 2007 July 27].
65. Wolmark N. A randomized phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following ac accompanied by correlative science studies to identify predictors of pathologic complete response. NSABP Foundation Inc.: National Library of Medicine Clinical Trials Database; 2007 [cited 2007 July 27].